Decoding Brain Waves Helps Identify Music, New Study Suggests

This undated image of the human brain was taken through scanning technology. REUTERS/FILE
This undated image of the human brain was taken through scanning technology. REUTERS/FILE
TT

Decoding Brain Waves Helps Identify Music, New Study Suggests

This undated image of the human brain was taken through scanning technology. REUTERS/FILE
This undated image of the human brain was taken through scanning technology. REUTERS/FILE

A new technique created by researchers at the University of Essex for monitoring brain waves can identify the music someone is hearing. The study was published on January 19, in the journal Scientific Reports.

The researchers hope the project could lead to helping people with severe communication disabilities such as locked-in syndrome or stroke sufferers by decoding language signals within their brains through non-invasive techniques.

Dr. Ian Daly from Essex's School of Computer Science and Electronic Engineering, who led the research, said, “This method has many potential applications. We have shown we can decode music, which suggests that we may one day be able to decode language from the brain.”

While there have been successful previous studies monitoring and reconstructing acoustic information from brain waves, many have used more invasive methods such as electrocortiography (ECoG), which involves placing electrodes inside the skull to monitor the actual surface of the brain.

Essex scientists wanted to find a less invasive way of decoding acoustic information from signals in the brain to identify and reconstruct a piece of music someone was listening to.

The research used a combination of two non-invasive methods—fMRI, which measures blood flow through the entire brain, and electroencephalogram (EEG), which measures what is happening in the brain in real time—to monitor a person's brain activity while they are listening to a piece of music.

Using a deep learning neural network model, the data was translated to reconstruct and identify the piece of music. Music is a complex acoustic signal, sharing many similarities with natural language, so the model could potentially be adapted to translate speech.

The eventual goal of this strand of research would be to translate thought, which could offer an important aid in the future for people who struggle to communicate, such as those with locked-in syndrome.

During the study, the participants listened to a series of 40-second pieces of simple piano music from a set of 36 pieces differing in tempo, pitch, harmony and rhythm. Using these combined data sets, the model was able to accurately identify the piece of music with a success rate of 71.8 percent.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”